Cooke L - Search Results

1

TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients.

Pandey R, Johnson N, Cooke L, Johnson B, Chen Y, Pandey M, Chandler J, Mahadevan D. Pandey R, et al. Among authors: cooke l. Cancers (Basel). 2021 Feb 3;13(4):597. doi: 10.3390/cancers13040597. Cancers (Basel). 2021. PMID: 33546249 Free PMC article.

2

Next generation sequencing identifies 'interactome' signatures in relapsed and refractory metastatic colorectal cancer.

Johnson B, Cooke L, Mahadevan D. Johnson B, et al. Among authors: cooke l. J Gastrointest Oncol. 2017 Feb;8(1):20-31. doi: 10.21037/jgo.2016.09.05. J Gastrointest Oncol. 2017. PMID: 28280605 Free PMC article.

3

Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.

Qi W, Morales C, Cooke LS, Johnson B, Somer B, Mahadevan D. Qi W, et al. Oncotarget. 2015 Dec 8;6(39):41976-87. doi: 10.18632/oncotarget.5659. Oncotarget. 2015. PMID: 26506516 Free PMC article.

4

Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.

Babiker HM, McBride A, Cooke LS, Mahadevan D. Babiker HM, et al. Expert Opin Investig Drugs. 2017 Sep;26(9):1063-1072. doi: 10.1080/13543784.2017.1360275. Epub 2017 Jul 30. Expert Opin Investig Drugs. 2017. PMID: 28745064 Review.

5

Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target.

Pandey R, Zhou M, Islam S, Chen B, Barker NK, Langlais P, Srivastava A, Luo M, Cooke LS, Weterings E, Mahadevan D. Pandey R, et al. Sci Rep. 2019 Dec 4;9(1):18347. doi: 10.1038/s41598-019-54545-9. Sci Rep. 2019. PMID: 31797958 Free PMC article.

6

Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma.

Engelhardt K, Riley C, Cooke L, Mahadevan D. Engelhardt K, et al. Among authors: cooke l. Curr Drug Discov Technol. 2006 Dec;3(4):231-43. doi: 10.2174/157016306780368108. Curr Drug Discov Technol. 2006. PMID: 17430101 Review.

7

Ublituximab for the treatment of CD20 positive B-cell malignancies.

Babiker HM, Glode AE, Cooke LS, Mahadevan D. Babiker HM, et al. Expert Opin Investig Drugs. 2018 Apr;27(4):407-412. doi: 10.1080/13543784.2018.1459560. Epub 2018 Apr 3. Expert Opin Investig Drugs. 2018. PMID: 29609506 Review.

8

Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma.

Islam S, Paek AL, Hammer M, Rangarajan S, Ruijtenbeek R, Cooke L, Weterings E, Mahadevan D. Islam S, et al. Among authors: cooke l. Oncotarget. 2018 Nov 13;9(89):35875-35890. doi: 10.18632/oncotarget.26251. eCollection 2018 Nov 13. Oncotarget. 2018. PMID: 30542505 Free PMC article.

9

Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.

Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO, Chen D, Miller TP, Mahadevan D. Qi W, et al. Leuk Res. 2013 Apr;37(4):434-9. doi: 10.1016/j.leukres.2012.10.017. Epub 2012 Nov 12. Leuk Res. 2013. PMID: 23153524 Free PMC article.

10

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).

Mahadevan D, Theiss N, Morales C, Stejskal AE, Cooke LS, Zhu M, Kurtzman D, Swart R, Ong E, Qi W. Mahadevan D, et al. Oncotarget. 2015 Feb 10;6(4):1954-66. doi: 10.18632/oncotarget.3021. Oncotarget. 2015. PMID: 25557174 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

325 results

Search Page

Filters